Necrosis News and Research

RSS

Detecting cancer with silica nanoparticles

Tumor necrosis factor-alpha is a widely accepted biomarker for cancer, but the minute amounts of this protein circulating in blood makes detecting the molecule and measuring its concentration accurately a technological challenge.

19 Sep 2006

Drug infliximab may help ease ulcerative colitis

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.

12 Sep 2006

The B7 family of co-regulatory ligands is implicated again in the pathogenesis of renal cell carcinoma progression

Previous reports from the group at Mayo Clinic have demonstrated that B7-H1 expression by renal cell carcinoma (RCC) is a marker of poor prognosis in both localized and metastatic RCC.

6 Sep 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

A tissue marker of poor prognosis in clear cell renal cell carcinoma

The search for molecular markers that further advance our knowledge of the biology of renal cell carcinoma (RCC) and assist in evaluating the diagnosis and prognosis of patients remains the subject of intense investigation.

20 Aug 2006

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Scientists find a cytokine against auto-immune hepatitis

There are about 400 million patients of hepatitis in the world. Some of them are suffering from autoimmune hepatitis, a disease in which the body's immune system attacks liver cells.

5 Jul 2006

Antegrade scrotal sclerotherapy for treating primary varicocele in children

This study by Zaupa et al evaluated the effectiveness and limitations of antegrade sclerotherapy (AS) for the treatment of primary varicocele in childhood.

19 Jun 2006

Central nervous system can sometimes send out signals that invite hostile immune system attacks

It may sound like a case of blame the victim, but researchers at Washington University School of Medicine in St. Louis have shown that cells in the central nervous system can sometimes send out signals that invite hostile immune system attacks.

18 Jun 2006

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006

Important insights into how cells regulate certain growth-proteins

Researchers here have discovered a new mechanism used by cells - and manipulated by retroviruses - to control the making of certain essential proteins, including some involved in cancer.

8 May 2006

Etanercept and chemo might reduce fatigue in cancer patients

Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.

3 May 2006

Study assesses formularies across Medicare drug plans

Medicare's new private stand-alone drug plans vary significantly - in terms of covered drugs, out-of-pocket costs for specific medications, and restrictions placed on the use of certain drugs - according to a new analysis released today by the Kaiser Family Foundation.

11 Apr 2006

MIT look at how cells make life-or-death decisions

The biological processes underlying diseases such as rheumatoid arthritis and cancer are fundamentally linked, and should be linked in how they are treated with drugs, a series of MIT studies indicates.

6 Apr 2006

Ingredient in red peppers inhibits prostate cancer in laboratory studies

Capsaicin is the pungent ingredient in red peppers and is presently used as a topical pain reliever. Now, a new study shows it may be justified to evaluate capsaicin for inhibiting prostate cancer (CaP) in patients.

5 Apr 2006

Thalidomide, Lenalidomide show promise against Lou Gehrig's disease

New animal research suggests that two well-studied drugs, thalidomide and its derivative, lenalidomide, might extend the survival of patients with the neurological disorder amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

9 Mar 2006

Attaching new cytokine to neural stem cells derived from bone marrow kills brain tumor cells

Attaching a recently discovered cytokine to neural stem cells derived from bone marrow, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have developed a tool to track and kill malignant brain tumor cells and provide long-term protection against their return.

1 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006